We’re proud to share that the DLT and PDT delivery and sensing system developed through the GlioLighT project, the pcGlio-DSS, has been selected by the European Commission’s Innovation Radar as a promising early-stage innovation emerging from EU-funded research!
This recognition places our work among a select group of pioneering technologies in Europe that are laying the foundation for future market opportunities and delivering cutting-edge contributions to their fields.
What is the Innovation Radar?
The Innovation Radar is a European Commission initiative that identifies high-potential innovations from EU-funded research and innovation projects. It highlights ideas that can shape Europe’s future by assessing their innovation potential, market maturity, and the capability of the innovating organisations.
Each innovation is evaluated using a data-driven methodology, with expert input from the Commission’s independent reviewers. The goal? To spotlight and support innovations on their journey from the lab to the marketplace.
Our Innovation: Early-Stage with Big Potential
Our product was assessed as being at the “Exploring” stage of market maturity. This classification recognises that while the innovation is still in the early phases of development, it shows clear potential to address emerging needs and open new market spaces in the future.
Furthermore, the Innovation Radar rated its market creation potential as “Moderate”, affirming that the pcGlio-DSS could drive meaningful change in cancer treatment—whether by improving existing practices, enabling new capabilities, or unlocking fresh opportunities.
Our Key Innovators
The Innovation radar highlighted our partners at Modulight, Aston University and LMU as key innovators in the development of the pcGlio-DSS. This highlights the hard work our key technology developers have put into the device, establishing themselves as major innovators in cutting-edge technology.
Why This Matters
This milestone validates the vision and foundational research of our team and partners. It shows that we are working on something with real potential to impact the future of Glioma treatment, even if it’s still early in its commercial journey.
Being recognized by the Innovation Radar offers us not only visibility, but also the opportunity to connect with other innovators, policymakers, and potential collaborators who share our ambition to build what’s next.
What’s Next?
We will continue to develop, test, and refine the pcGlio-DSS, exploring new paths to bring it closer to market. Our focus now is on advancing the technology, understanding user needs, and building the ecosystem necessary to support its future growth.
🔗 Check out our listing on the Innovation Radar platform
Stay tuned for our launch on the website!
—
Thank you to all of our partners, collaborators, and the European Commission for supporting this journey. Together, we’re shaping the future—step by step.
